




(86) Date de dépôt PCT/PCT Filing Date: 2003/03/20
 (87) Date publication PCT/PCT Publication Date: 2003/10/02
 (85) Entrée phase nationale/National Entry: 2004/09/17
 (86) N° demande PCT/PCT Application No.: US 2003/008898
 (87) N° publication PCT/PCT Publication No.: 2003/080065
 (30) Priorités/Priorities: 2002/03/20 (60/365,913) US;
 2003/01/29 (60/443,585) US

(51) Cl.Int.⁷/Int.Cl.⁷ A61K 31/55, A61P 25/18, C07D 281/16
 (71) Demandeur/Applicant:
 TEVA PHARMACEUTICAL INDUSTRIES LTD., IL
 (72) Inventeurs/Inventors:
 LIFSHITZ-LIRON, REVITAL, IL;
 KOVALEVSKI-ISHAI, ETI, IL;
 DOLITZKY, BEN-ZION, IL;
 WIZEL, SHLOMIT, IL;
 LIDOR-HADAS, RAMI, IL
 (74) Agent: HEENAN BLAIKIE LLP

(54) Titre : FORMES CRISTALLINES D'HEMIFUMARATE DE QUETIAPINE

(54) Title: CRYSTALLINE FORMS OF QUETIAPINE HEMIFUMARATE



(I)

(57) **Abrégé/Abstract:**

The present invention relates to novel crystalline forms of quetiapine hemifumarate (I), denominated quetiapine hemifumarate form II and quetiapine hemifumarate form III. These novel crystalline forms of quetiapine hemifumarate have been characterized by methods including x-ray powder diffraction (XRD), Fourier transform IR spectroscopy (FTIR), differential scanning calorimetry (DSC), and thermal gravimetric analysis (TGA). Methods for preparation of the novel crystalline quetiapine hemifumarate form II as its chloroform solvate and its dichloromethane solvate, form III as its chloroform solvate, and form I are provided.